ImPact Biotech to Present Interim Phase 3 Data from ENLIGHTED Study of Padeliporn VTP in Low Grade UTUC at Upcoming Medical Conferences
Preliminary results from Phase 3 ENLIGHTED study in low grade upper tract urothelial cancer (UTUC) to be presented at AUA and ASCO Trial design for Phase 1 study of Padeliporfin VTP in pancreatic ductal adenocarcinoma (PDAC) to be presented at ASCO TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology … Continued
ImPact Biotech Announces Appointment of Eyal Morag, M.D. as Chief Medical Officer
TEL AVIV, Israel, Dec. 18, 2023 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy to treat a range of solid tumors, today announced the appointment of Eyal Morag, M.D., as Chief Medical Officer (CMO). Dr. Morag brings extensive experience as a practicing clinical radiologist, specializing in … Continued
ImPact Biotech Receives FDA Clearance of IND Application for Padeliporfin VTP in Pancreatic Cancer
Phase 1 clinical trial expected to initiate in 1H 2024 IND clearance in third indication reflects broad platform potential for Padeliporfin VTP across a range of solid tumors TEL AVIV, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) — ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin Vascular Targeted Photodynamic (VTP) therapy to treat … Continued
ImPact Biotech Announces Research Collaboration to progress a treatment to arrest Pathologic Myopia using its Padeliporfin minimally invasive platform
ImPact Biotech to collaborate with Maastricht University researchers to progress a treatment to arrest the progressive condition Pathologic Myopia, a leading cause of irreversible sight impairment and blindness among adults TEL AVIV, August 13, 2023 — ImPact Biotech, a leader in photodynamic therapy, recently announced an agreement with Maastricht University to collaborate in research focused … Continued
ImPact Biotech receives FDA Clearance for Padeliporfin VTP Phase 1 Clinical Program in Peripheral Lung Cancer
Padeliporfin VTP Phase 1 trial in Peripheral Non-Small Cell Lung Cancer to start by end Q4 2023 TEL AVIV, August 1, 2023 — ImPact Biotech, the IMmune Photo Activated Cancer Treatment (IMPACT) specialist announces the U.S. Food and Drug Administration cleared ImPact’s clinical investigation plan of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy for the treatment of patients with Peripheral Lung Cancer. … Continued